Targeting chronic myeloid leukemia stem cells

Helgason, V. , Young, G. and Holyoake, T. (2010) Targeting chronic myeloid leukemia stem cells. Current Hematologic Malignancy Reports, 5(2), pp. 81-87. (doi: 10.1007/s11899-010-0043-0)

Full text not currently available from Enlighten.

Publisher's URL:


Chronic myeloid leukemia (CML) arises as a consequence of a chromosomal translocation giving rise to the Philadelphia chromosome and Bcr-Abl oncogene. CML is a clonal disease of stem cell origin and an excellent example of a malignancy in which tumor-initiating cells may hold the key to disease eradication. The known molecular basis of CML has enabled the development of Abl-specific tyrosine kinase inhibitors, such as imatinib mesylate. However, the success of tyrosine kinase inhibitors, as rationally designed first-line therapies, has been tempered by problems of disease persistence and resistance. Residual disease has been shown to be enriched within the stem cell compartment and to persist at stable levels for up to 5 years of complete cytogenetic response. This finding has led to further searches for novel strategies aimed at eliminating these cells; such strategies may be essential in achieving cure. The most significant recent findings are discussed in this review.

Item Type:Articles
Glasgow Author(s) Enlighten ID:Holyoake, Professor Tessa and Helgason, Professor Vignir
Authors: Helgason, V., Young, G., and Holyoake, T.
College/School:College of Medical Veterinary and Life Sciences > School of Cancer Sciences
Journal Name:Current Hematologic Malignancy Reports

University Staff: Request a correction | Enlighten Editors: Update this record